Follow

Sensidose AB

Spotlight Stock Market (Sweden)

Sensidose is a pharmaceutical company that has developed an innovative new system for individualized dosing of pharmaceutical tablets, allowing for fine-tuned, precision drug therapy.
Go to market

Sector:
HEALTH CARE
>
Pharmaceuticals
Media
Exercise
Price
9.00 SEK
Exercise period(s)
01 Jun - 15 Jun 2023
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
SENSI
SE0017232671
Spotlight Stock Market
Sweden (SE)
Details of share in Sensidose AB with ticker SENSI
Status
Active
Currency
SEK
First trading date
12 May 2022
Type
Price
Pre-money
Time
Files
Exercise
9.00 SEK
107.63M SEK
01 Jun - 15 Jun 2023
Option exercise terms for SENSI TO1
Type
Ticker
ISIN
Market
SHARE
SENSI
SE0017232671
Spotlight Stock Market
Sweden (SE)
Details of share in Sensidose AB with ticker SENSI
Status
Active
Currency
SEK
First trading date
12 May 2022
Type
Ticker
ISIN
Market
OPTION
SENSI TO1
SE0017615636
Spotlight Stock Market
Sweden (SE)
Details of option in Sensidose AB with ticker SENSI TO1
Status
Archived
Currency
SEK
Trading period
12 May 2022 - 13 Jun 2023
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share for SEK 9.0 during the period June 1, 2023 - June 15, 2023.
Type
Price
Pre-money
Time
Files
Exercise
9.00 SEK
107.63M SEK
01 Jun - 15 Jun 2023
Option exercise terms for SENSI TO1
People
Jack Spira
CEO
Per Nilsson
Chairman of the board
Sten-Magnus Aquilonius
Board member
Lasse Tenerz
Board member
Jack Spira
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Vetenskapsvägen 10
Zip code
191 38
City/district
Sollentuna
Country
Sweden (SE)
Registration number
556550–3074
LEI code
391200HM0WOIJQMXGT93
First trade date
12 May 2022
Registration date
23 Jan 1998
Short name
SENSI

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More